Update on the optimal use of voriconazole for invasive fungal infections
Open Access
- 1 February 2011
- journal article
- Published by Taylor & Francis Ltd in Infection and Drug Resistance
- Vol. 4, 43-53
- https://doi.org/10.2147/idr.s12714
Abstract
Voriconazole is an extended-spectrum triazole with excellent bioavailability that has now become the treatment of choice for aspergillosis. It has a unique side effect profile compared with other azoles, as well as a number of clinically important drug–drug interactions. These factors, along with a correlation between increased serum levels and improved outcomes, have prompted an interest in therapeutic drug monitoring of this agent. The pharmacology and clinical outcomes data of voriconazole are presented in this review.Keywords
This publication has 87 references indexed in Scilit:
- Frequency and Evolution of Azole Resistance inAspergillus fumigatusAssociated with Treatment Failure1Emerging Infectious Diseases, 2009
- Aggressive Cutaneous Squamous Cell Carcinoma Associated with Prolonged Voriconazole Therapy in a Renal Transplant PatientAmerican Journal of Transplantation, 2008
- Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2008
- An Open-Label Comparative Pilot Study of Oral Voriconazole and Itraconazole for Long-Term Treatment of ParacoccidioidomycosisClinical Infectious Diseases, 2007
- Torsades de pointes associated with voriconazole useTransplant Infectious Disease, 2007
- Correlation of MIC with Outcome for Candida Species Tested against Voriconazole: Analysis and Proposal for Interpretive BreakpointsJournal of Clinical Microbiology, 2006
- Mutations in Aspergillus fumigatus Resulting in Reduced Susceptibility to Posaconazole Appear To Be Restricted to a Single Amino Acid in the Cytochrome P450 14α-DemethylaseAntimicrobial Agents and Chemotherapy, 2003
- Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patientsClinical Pharmacology & Therapeutics, 2002
- In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: Review of the literatureMycopathologia, 2001
- Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazoleClinical Pharmacology & Therapeutics, 1994